IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)
An International Open Access, Peer-reviewed, Refereed Journal

CRISPR CAS9 DRUG DELIVERY SYSTEM

Yanamala Reddy Sukeshini, A. Lavanya

Student, Faculty Of Pharmaceutics

Krishna Teja Pharmacy College

Abstract:

The CRISPR-Cas9 system has revolutionized gene editing, offering unprecedented precision and efficiency. However, delivering Cas9 protein to specific cells and tissues remains a significant challenge. Here, we present a novel drug delivery system for targeted CRISPR-Cas9 protein delivery. Our approach utilizes a nanoparticle-based platform to encapsulate Cas9 protein and guide RNA (gRNA), ensuring stable and efficient delivery to target cells. The nanoparticles are engineered with targeting ligands to facilitate cell-specific uptake and reduce off-target effects. In vitro and in vivo studies demonstrate the efficacy of our delivery system in achieving targeted gene editing. We observe significant reductions in off-target effects and improved specificity compared to traditional viral vector-based approaches. This CRISPR-Cas9 protein delivery system holds promise for the treatment of genetic diseases, offering a safer and more efficient alternative to existing gene editing therapies. Future studies will focus on optimizing the delivery system for clinical applications and exploring its potential in treating a range of genetic disorders.

Introduction:

The CRISPR technology has revolutionized genome editing, effectively creating model organisms across various species. Over the past three decades, CRISPR has undergone remarkable transformation - from mysterious sequences of unknown biological function to a powerful genome-editing tool.The discovery of CRISPR began in 1987 when Yoshizumi Ishino and colleagues identified a unique pattern of 29-nucleotide repeats in Escherichia coli, interspersed with short non-repetitive sequences.This foundational finding paved the way for subsequent research, culminating in the development of CRISPR-Cas9, a precise and efficient genome-editing technology. [2]

In 2012, researchers made a significant breakthrough, showing that Cas9–CRISPR (cr)RNA complexes from two bacterial species, Streptococcus pyogenes and Streptococcus thermophilus, possessed RNA-guided endonuclease activity in vitro. [1]

Genome editing involves modifying cell lines or animal organs to alter gene function, achieving either gain- or loss-of-function through various techniques, including:

Gene knockout (deletion)

Mutagenesis (introducing specific mutations)

Gene labeling (tagging genes for tracking)

Gene activation (enhancing gene expression) [3]

He CRISPR/Cas9 system is a revolutionary gene-editing tool that induces precise modifications by creating:

Double-strand breaks (DSBs)

Single-strand nicks

Since its emergence, CRISPR-Cas9 technology has transformed the gene editing landscape with its unparalleled precision and programmability. This groundbreaking tool enables targeted DNA modifications, holding immense promise for treating a wide range of diseases, including genetic disorders, cancers, and infectious diseases. However, the successful clinical implementation of CRISPR-Cas9 hinges on the development of efficient delivery systems that accurately target specific cells or tissues while mitigating off-target effects and toxicity. In drug discovery, genome engineering has played a pivotal role in identifying disease-causing genes. These identified genes are then validated in physiologically relevant preclinical animal models to confirm their role in disease pathology. Both forward and reverse genetic screening approaches have successfully pinpointed disease-causing mutations, such as:

PCSK9 mutations associated with cardiovascular disease

BRCA1 mutations linked to breast cancer

BCR-ABL1 fusion mutations driving chronic myeloid leukemia (CML)

These breaks occur at specific locations determined by guide ribonucleic acids (RNAs) that bind to the protospacer adjacent motif (PAM) sequence.The cellular response to DSBs triggers DNA repair mechanisms, leading to targeted gene mutations through:

Non-homologous end joining (NHEJ), resulting in insertions or deletions (indels)

Homology-directed repair (HDR), enabling precise gene editing [1,3]

CRISPR-Cas9's versatility extends beyond editing, as mutated Cas9 variants facilitate:

Gene regulation: precise control over gene expression

Live-cell imaging: visualization of genomic regions

These applications enable researchers to study gene function, chromatin dynamics, and genome organization across various species. [4]

Effective delivery of CRISPR-Cas9 components is a critical challenge, requiring navigation through complex biological environments to reach target cells. To overcome this hurdle, researchers have investigated both viral and non-viral delivery methods, each with its advantages and limitations. This review presents a comprehensive analysis of:

Current strategies for CRISPR-Cas9 delivery

Recent innovations and breakthroughs

Future directions for optimizing delivery systems.[4]

Figure 1- CRISPR / Cas 9 genome-editing system in human stem cells

BASIC FLOWCHART OF CRISPR-CAS9 -MEDIATED GENOME MODIFICATION IN TARGET CELL:

Target site selection [gene of interest]

↓

SgRNA design [tracrRNA + 20bp PAM] Optimized cas9 protein

↓

Expression vector design [pakeging of grRNA with cas9 and suitable promoter]

↓

Expression vectors are introduced in to target cells

↓

Screening of putative transformed cells [screening, copy, number analysis]

↓

Estimation the protein level [ELISA, western blotting]

↓

Further analysis [off-target effects]

Section 1: Viral Vectors in CRISPR Delivery

Adeno-associated Viruses (AAVs): Adeno-associated viruses (AAVs) are among the most widely used viral vectors for CRISPR delivery due to their ability to achieve high transduction efficiency and stable integration into host genomes. AAVs are relatively non-pathogenic and have a lower risk of causing immune responses compared to other viral vectors. However, their utility is limited by several factors, including a restricted packaging capacity (approximately 4.7 kb), which constrains the size of the CRISPR components that can be delivered.

Recent advances in AAV technology have focused on improving their specificity and reducing immunogenicity. Engineered AAV serotypes and capsid modifications have shown promise in enhancing tissue-specific targeting and reducing unwanted immune responses. For instance, synthetic biology approaches are being used to create AAV variants with improved tropism for specific cell types, which could enhance the efficacy of CRISPR-based therapies **[5]**

Lentiviral and Adenoviral Vectors: Lentiviral vectors, derived from HIV-1, are effective for delivering CRISPR components into both dividing and non-dividing cells. They offer long-term gene expression and integration into the host genome, making them suitable for applications requiring stable gene editing. However, the risk of insertional mutagenesis, where the integration of the viral DNA disrupts critical genes or regulatory elements, remains a concern **[4]**

Adenoviral vectors, on the other hand, provide high-efficiency transduction and can accommodate larger gene payloads compared to AAVs. However, they are associated with strong immune responses, which can limit their therapeutic applications and lead to rapid clearance from the host **[3].** Recent strategies to mitigate these issues include the use of adenoviral vectors with modified viral proteins to reduce immunogenicity and enhance the persistence of transgene expression.

Section 2: Non-Viral Delivery Systems:

Nanoparticle Systems: Nanoparticle-based delivery systems have emerged as a promising alternative to viral vectors for CRISPR delivery. Lipid-based nanoparticles (LNPs) and polymer-based nanoparticles are two major categories of non-viral carriers that have shown potential in improving the efficiency and safety of CRISPR-Cas9 delivery.

Lipid Nanoparticles (LNPs): Lipid nanoparticles are well-known for their role in mRNA delivery, with several LNP-based vaccines having received FDA approval. Their application to CRISPR delivery has also been explored, particularly for reducing cellular stress and improving delivery efficiency. LNPs can encapsulate CRISPR-Cas9 components and protect them from degradation while facilitating cellular uptake through endocytosis **[6]**

Recent advancements in lipid nanoparticle formulations include the development of ionizable lipids, which enhance endosomal escape and facilitate the release of CRISPR components into the cytoplasm. Additionally, modifications to lipid compositions and nanoparticle sizes are being optimized to improve targeting and reduce off-target effects **[3]**

Polymer-Based Nanoparticles: Polymeric nanoparticles offer several advantages, including the ability to customize their properties for specific applications. These nanoparticles can be engineered to have controlled release profiles, improved stability, and enhanced cellular uptake. Polymers such as polyethylenimine (PEI) and poly(lactic-co-glycolic acid) (PLGA) are commonly used to form nanoparticles for gene delivery **[4]**

Despite their potential, polymer-based nanoparticles face challenges related to toxicity and degradation. The balance between polymer stability and biodegradability is crucial to ensure effective and safe delivery of CRISPR components. Innovations in polymer chemistry and nanoparticle design are addressing these issues and improving the overall performance of polymer-based delivery systems

Section 3: Ribonucleoprotein (RNP)-Based Delivery

RNP Complexes: Ribonucleoprotein (RNP) delivery involves pre-forming complexes of the Cas9 protein and guide RNA (gRNA), which are then introduced into target cells. This approach offers several advantages over plasmid-based delivery, including reduced risk of off-target effects and lower potential for immune responses **[7]**

RNP-based delivery systems can be used in conjunction with various carrier technologies, including nanoparticles and hydrogels, to enhance their stability and efficiency. Recent advancements have focused on optimizing RNP formulations to improve their cellular uptake and activity. For instance, strategies to protect RNPs from degradation and enhance their release within target cells are being actively investigated **[1,5]**

Comparative Analysis: Compared to plasmid-based delivery, RNP-based methods offer several benefits, including reduced off-target effects and a shorter duration of gene editing activity. This makes RNPs particularly suitable for applications where transient gene editing is desired, such as in certain therapeutic contexts **[2]**However, the challenges associated with RNP delivery include the need for efficient and stable carriers to ensure the successful introduction of RNPs into cells.

Section 4: Emerging Techniques in CRISPR Delivery

Mechanical Delivery Methods: Mechanical methods such as electroporation and microinjection offer high-efficiency delivery of CRISPR-Cas9 components into cells. Electroporation uses electrical fields to create temporary pores in cell membranes, allowing the entry of CRISPR components. This method has been successfully applied in various cell types and is particularly useful for ex vivo applications **[2]**

Filtration-based methods, such as filtroporation, combine mechanical and chemical approaches to enhance the delivery of CRISPR components. These techniques are being explored to improve the efficiency of CRISPR delivery while minimizing cell damage and maintaining cell viability **[7]**

Hydrogel-Based Systems: Hydrogels have emerged as a novel delivery system for CRISPR-Cas9 components, offering several advantages, including biocompatibility, controlled release, and localized delivery. Hydrogels can be engineered to encapsulate CRISPR components and release them gradually over time, providing sustained gene editing activity

Recent developments in hydrogel technology include the incorporation of stimuli-responsive materials that can release CRISPR components in response to specific environmental triggers, such as changes in pH or temperature. These advancements are enhancing the precision and control of CRISPR delivery **[2]**

Section 5: Challenges and Future Directions

Biological Barriers: Overcoming biological barriers remains a significant challenge in CRISPR delivery. These barriers include the efficient escape of CRISPR components from endosomes, penetration through cellular membranes, and targeting specific cell types. Advances in nanotechnology and carrier design are addressing these issues, but further improvements are needed to enhance the overall efficiency of CRISPR delivery **[8]**

Immunogenicity and Safety Concerns: Immunogenicity is a major concern for both viral and non-viral delivery systems. The potential for immune responses against delivery vehicles or CRISPR components can limit therapeutic efficacy and lead to adverse effects. Researchers are developing strategies to minimize immunogenicity, including the use of non-immunogenic carriers and optimizing delivery formulations to reduce immune activation **[2]**

Personalized Medicine: The future of CRISPR-Cas9 technology lies in its integration into personalized medicine. Tailoring delivery systems to individual patients' genetic profiles and disease conditions has the potential to enhance the efficacy and safety of CRISPR-based therapies. Advances in genomics, nanotechnology, and biomaterials will play a crucial role in achieving this goal, enabling precise and individualized treatments **[3,4].**

OVERVIEW:

CRISPR-Cas9 Technology: Originally used for gene editing, CRISPR-Cas9 is a system that allows for precise targeting and modification of DNA within cells. Researchers are now harnessing this technology for therapeutic applications beyond gene editing, including drug delivery.

Mechanism: CRISPR systems can be programmed to target specific genes or DNA sequences within cells. When coupled with drug delivery mechanisms, CRISPR can be used to deliver therapeutic agents directly to the genetic material of cells, offering highly specific treatment options**[9].**

Recent Developments and Applications:

Gene Therapy: CRISPR-Cas9 has been used in clinical trials for treating genetic disorders like sickle cell anemia and muscular dystrophy. By correcting mutations at the DNA level, it offers a potential cure rather than just symptom management.

Cancer Treatment: Researchers are exploring CRISPR to deliver anticancer drugs directly to tumor cells or to modify immune cells to better target cancer. This can potentially reduce side effects and improve the efficacy of cancer treatments.

Infectious Diseases: CRISPR-based systems are being investigated for their ability to target and disable viral DNA, offering a novel approach to treating chronic viral infections like HIV **[10,11]**

Delivery Mechanisms:

Viral Vectors: Adeno-associated viruses (AAVs) are commonly used to deliver CRISPR components to specific cells. These vectors are engineered to carry the Cas9 enzyme and guide RNA to the target site.

Non-Viral Vectors: Lipid nanoparticles and polymer-based systems are being explored as alternatives to viral vectors, offering potentially safer and more controlled delivery.

Exosomes: These naturally occurring vesicles are being investigated as a delivery vehicle for CRISPR components, potentially improving targeting and reducing immune responses**.[12]**

RECENT EXPERIMENTS:

Recent experiments with CRISPR-Cas9 protein delivery systems are showcasing groundbreaking advances, particularly in cancer treatment and gene editing in living animals. In 2024, researchers from the University of California, Berkeley, developed a highly targeted CRISPR delivery system using enveloped delivery vehicles. This system has demonstrated the ability to edit genes in living animals with high precision, significantly advancing in vivo gene therapy techniques. The study emphasizes the importance of targeting specific cells and tissues, which is a critical challenge in CRISPR delivery Science Daily, Another promising area of research is the use of nanotechnology-based delivery systems for CRISPR-Cas9 in cancer treatment. These systems leverage smart nanocarriers that can release CRISPR components in response to specific intracellular or extracellular signals. This approach improves the precision and reduces off-target effects, making it a valuable tool in oncology. However, the research is still in its early stages, with ongoing efforts to optimize these non-viral vectors for better safety and efficiency, These recent experiments highlight the exciting potential of CRISPR-Cas9 delivery systems while also underscoring the need for further research to address challenges such as targeting specificity, off-target effects, and safety concerns. These developments set the stage for future innovations in gene therapy and personalized medicine.

Challenges:

Off-Target Effects: While CRISPR is highly specific, there is still a risk of off-target modifications, which could lead to unintended consequences.

Delivery Efficiency: Ensuring that CRISPR components reach the correct cells and tissues at therapeutic levels remains a challenge, particularly for diseases that affect a large number of cells.

Ethical and Regulatory Issues: The ability to edit human DNA raises ethical concerns, particularly regarding germline editing. Regulatory bodies are closely scrutinizing the use of CRISPR in clinical settings.

Why It's Considered One of the Best and New:

Revolutionary Potential: CRISPR-Cas9 represents a paradigm shift in medicine, offering the potential to not just treat, but cure, genetic diseases at their source.

Expanding Research and Applications: The field is rapidly evolving, with new delivery systems and applications being explored, making it a hotbed of innovation in drug delivery and gene therapy.

Personalized Medicine: CRISPR technology could lead to highly personalized treatments, tailored to an individual's genetic makeup, further pushing the boundaries of precision medicine.

In summary, CRISPR-Cas9-based delivery systems are at the forefront of biomedical research, offering innovative solutions for gene therapy, cancer treatment, and beyond. Their precision, versatility, and potential for long-lasting effects make them one of the most exciting new developments in drug delivery technology.

Advantages:

High Precision and Specificity: CRISPR-Cas9 systems can target specific DNA sequences with remarkable accuracy, reducing the likelihood of off-target effects and making gene editing more precise.

Versatility: CRISPR-Cas9 can be used to edit, delete, or insert genes across various organisms, making it a versatile tool in genetic research and therapy.

Potential for Treating Genetic Disorders: CRISPR-Cas9 holds the promise of curing genetic disorders by directly correcting mutations at their source, offering a potential one-time treatment.

Rapid and Cost-Effective: Compared to older gene-editing technologies, CRISPR-Cas9 is faster and more cost-effective, enabling more widespread adoption in research and clinical applications.

Expanding Delivery Options: Various delivery methods, such as viral vectors, lipid nanoparticles, and physical methods like electroporation, offer multiple approaches to suit different therapeutic needs.

Potential for Cancer Therapy: CRISPR-Cas9 can be used to target cancer cells by knocking out oncogenes or reactivating tumor suppressor genes, showing promise in cancer treatment.

Advancements in Delivery Mechanisms: Innovations in delivery systems, such as biodegradable nanoparticles, improve the efficiency and safety of CRISPR-Cas9 delivery, reducing the risk of immune responses and toxicity.

Therapeutic Flexibility: CRISPR-Cas9 can be adapted for various therapeutic modalities, including gene knockout, gene repair, and base editing, providing a flexible platform for different diseases.

Scalable Production: The ease of designing and producing CRISPR-Cas9 components makes it scalable for large-scale therapeutic applications, including clinical trials and future treatments.

Continuous Advancements: Ongoing research and development are continuously improving CRISPR-Cas9 technology, addressing current limitations and expanding its therapeutic potential.

Disadvantages:

Off-Target Effects: Despite its precision, CRISPR-Cas9 can still cause off-target mutations, potentially leading to unintended genetic changes and adverse effects.

Delivery Challenges: Efficient and safe delivery of CRISPR-Cas9 components into target cells remains a significant hurdle, particularly for in vivo applications.

Immune Responses: Delivery of CRISPR-Cas9 via viral vectors can trigger immune responses, potentially reducing the efficacy of the treatment and causing harmful side effects.

Limited Efficiency in Some Tissues: Certain tissues and organs are more difficult to target with current delivery systems, limiting the effectiveness of CRISPR-Cas9 in some therapeutic areas.

Potential for Unwanted Mutations: In some cases, CRISPR-Cas9 may cause unintended mutations in non-target genes, raising concerns about long-term safety and the possibility of creating harmful mutations.

Ethical and Regulatory Challenges: The potential for CRISPR-Cas9 to be used in germline editing raises significant ethical and regulatory concerns, particularly regarding the long-term consequences of altering human embryos.

Technological Complexity: The technology is still evolving, and there are complexities in optimizing CRISPR-Cas9 delivery for different types of cells and tissues, requiring extensive research and development.

Unpredictable Outcomes: The effects of CRISPR-Cas9 editing can sometimes be unpredictable, leading to variable outcomes that complicate clinical applications and patient safety.

Potential for Resistance: Cells may develop resistance to CRISPR-Cas9 editing, particularly in the context of cancer treatment, limiting the long-term effectiveness of the therapy.

High Costs in Clinical Translation: While the research and experimental phases may be cost-effective, translating CRISPR-Cas9 therapies into clinical practice can be expensive, involving extensive testing, regulatory approvals, and large-scale production challenges.

Conclusion: This review highlights the significant progress made in CRISPR-Cas9 drug delivery systems and the challenges that remain. Both viral and non-viral vectors offer unique advantages, but the development of safer and more efficient delivery methods is crucial for the successful application of CRISPR-Cas9 in therapeutic contexts. Ongoing research into nanoparticles, hydrogels, and RNP-based systems holds great promise for advancing CRISPR-Cas9 therapies and addressing the current limitations.

References:

1.Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews, 65(1), 36–48.

2. Liang, P., Sallam, K., Wu, H., Li, Y., Itzhaki, I., Garg, P., et al. (2016). Patient-specifc and genome-edited induced pluripotent stem cell–derived cardiomyocytes elucidate single-cell phenotype of Brugada syndrome. Journal of the American College of

Cardiology, 68(19), 2086–2096.

3. Yang, T.-C., Chang, C.-Y., Yarmishyn, A. A., Mao, Y.-S., Yang, Y.-P., Wang, M.-L., et al. (2020). Carboxylated nanodiamondmediated CRISPR-Cas9 delivery of human retinoschisis mutation into human iPSCs and mouse retina. Acta Biomaterialia, 101, 484–494

4.Gee, P., Lung, M. S., Okuzaki, Y., Sasakawa, N., Iguchi, T., Makita, Y., et al. (2020). Extracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping. Nature Communications, 11(1), 1–18.

5.Lee, K., Conboy, M., Park, H. M., Jiang, F., Kim, H. J., Dewitt, M. A., et al. (2017). Nanoparticle delivery of Cas9 ribonucleo protein and donor DNA in vivo induces homology-directed DNA repair. Nature Biomedical Engineering, 1(11), 889–901.

6.Shahbazi, R., Sghia-Hughes, G., Reid, J. L., Kubek, S., Haworth, K. G., Humbert, O., et al. (2019). Targeted homology-directed repair in blood stem and progenitor cells with CRISPR nanoformulations. Nature Materials, 18(10), 1124–1132

7. Lin, Y., Wu, J., Gu, W., Huang, Y., Tong, Z., Huang, L., et al. (2018). Exosome–liposome hybrid nanoparticles deliver CRISPR/Cas9 system in MSCs. Advanced Science, 5(4), 170061

8. Mangeot, P. E., Risson, V., Fusil, F., Marnef, A., Laurent, E., Blin, J., et al. (2019). Genome editing in primary cells and in vivo using viral-derived Nanoblades loaded with Cas9-sgRNA ribonucleoproteins. Nature Communications, 10(1), 1–15

9. Charlesworth, C. T., Deshpande, P. S., Dever, D. P., Camarena, J., Lemgart, V. T., Cromer, M. K., et al. (2019). Identifcation of preexisting adaptive immunity to Cas9 proteins in humans. Nature Medicine, 25(2), 249–254

8. Butterfield, G. L. et al. Evolution of a designed protein assembly encapsulating its own RNA genome. Nature 552, 415–420 (2017)

9. Kishimoto, T. K. & Samulski, R. J. Addressing high dose AAV toxicity — 'one and done' or 'slower and lower'? Expert Opin. Biol. Ther. 22, 1067–1071 (2022).

10. Boutin, S. et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum. Gene Ther. 21, 704–712 (2010).

11. Zischewski, J., Fischer, R., & Bortesi, L. (2017). Detection of on-target and off-target mutations generated by CRISPR/ Cas9 and other sequence-specific nucleases. Biotechnology Advances, 35(1), 95–104.

12. Charlesworth, C. T., Deshpande, P. S., Dever, D. P., Camarena, J., Lemgart, V. T., Cromer, M. K., et al. (2019). Identifcation of preexisting adaptive immunity to Cas9 proteins in humans. Nature Medicine, 25(2), 249–254